Barclays analyst Carter Gould raised the firm’s price target on Cytokinetics to $100 from $58 and keeps an Overweight rating on the shares. The analyst says aficamten sets up as a new standard in hypertrophic cardiomyopathy following the positive topline results from the SEQUOIA-HCM Phase 3 study. The firm updated its model to reflect the “de-risking” from SEQUOIA and new share assumptions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CYTK:
- Here’s Why Cytokinetics (NASDAQ:CYTK) Stock Surged Yesterday
- Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
- Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy
- Cytokinetics seeing ‘strong interest’ from strategic suitors, Dealreporter says
- Oppenheimer, Wedbush say buy these biotech stocks for 2024